TY  - JOUR
AU  - Coenen, H. H.
AU  - Elsinga, P.H.
AU  - Iwata, R.
AU  - Kilbourn, M.R.
AU  - Pillai, M.R.A.
AU  - Rajan, M.G.R.
AU  - Wagner, H.N.
AU  - Zaknun, J.
TI  - Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences
JO  - Nuclear medicine and biology
VL  - 37
SN  - 1872-9614
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - PreJuSER-7089
SP  - 727 - 740
PY  - 2010
N1  - The Consultants acknowledge the IAEA for its interest and activities in this important field. The authors from the IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head, Industrial Applications and Chemistry Section, Dr. M. Dondi, Head, Nuclear Medicine Section, and Dr N. Ramamoorthy, Director-NAPC, International Atomic Energy Agency for their support and encouragement.
AB  - Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.
KW  - Animals
KW  - Fluorodeoxyglucose F18: diagnostic use
KW  - Humans
KW  - Neoplasms: radionuclide imaging
KW  - Nervous System Diseases: radionuclide imaging
KW  - Radiopharmaceuticals: diagnostic use
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - Fluorodeoxyglucose F18 (NLM Chemicals)
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
C6  - pmid:20870148
UR  - <Go to ISI:>//WOS:000282803500001
DO  - DOI:10.1016/j.nucmedbio.2010.04.185
UR  - https://juser.fz-juelich.de/record/7089
ER  -